Tools
Stock profile

Taysha Gene Therapies, Inc. (TSHA)

TSHA · Latest close $3.99 as of Nov 18, 2026 · 13F data as of Jun 30, 2026 (2026 Q2)
Latest close
$3.99
As of Nov 18, 2026
Tracked funds holding
6 of 149
2026 Q2 13F filings
Opened / added
1 / 2
vs previous quarter
Trimmed / exited
2
vs previous quarter

Taysha Gene Therapies, Inc. (TSHA) is held by 6 of 149 tracked super-investor funds (144 filed in Q2) in 2026 Q2 13F filings, with 1 fund opening new positions, 2 funds adding, and 2 funds trimming or exiting versus the previous quarter. Latest close $3.99 as of Nov 18, 2026.

Data as of Nov 18, 2026 (prices) · 2026 Q2 13F filings (quarter ended Jun 30, 2026) · Latest Form 4: none in the last 90 days · Congress to Nov 16, 2026.

Funds
2026 Q2 13F
Fundamentals
Revenue · FY2025
Red flags
screens flagged
Short interest
as of Oct 15, 2026
Holdings · Charts · All institutions · Fundamentals · Short interest · Fails to deliver · Insider trading · 5% holders · Planned sales · Politician trading · Committee jurisdiction · Government relations · Screens & lenses · Signal record · Related stocks · Recent 8-K

Funds holding this

Avoro Capital Advisors · RA Capital Management · RTW Investments — 6 tracked funds hold TSHA. See all holders.

Insider and Congress activity

No insider open-market activity or Congress trades reported for this stock in the recent window. Insider trading · Politician trading.

Often held alongside

ACADIA PHARMACEUTICALS INC (ACAD) · FAETH THERAPEUTICS INC (FTH) · Kodiak Sciences Inc. (KOD) · KYMERA THERAPEUTICS INC (KYMR) · MADRIGAL PHARMACEUTICALS INC (MDGL) — stocks the same funds also hold. See all related stocks.

Super-investor holdings · 2026 Q2

FundPortfolio weightSharesChange vs prev. quarter
Avoro Capital Advisors1.46%23,888,888ADDED (+10.1%) Q3 filed Nov 16
RA Capital Management1.39%23,555,648HELD Q3 filed Nov 16
RTW Investments0.79%13,560,258TRIMMED (-0.9%) Q3 filed Nov 16
OrbiMed Advisors0.25%2,000,000NEW Q3 filed Nov 16
Baker Bros. Advisors0.14%4,004,756HELD Q3 filed Nov 16
Polen Capital Management0.03%489,219ADDED (+53.0%) Q3 filed Nov 13
Deerfield Management——EXITED

Source: SEC Form 13F filings, quarter ended Jun 30, 2026. Change labels compare each fund’s 2026 Q2 filing with its previous filing. Fund counts aggregate every share class mapped to this ticker.

Price change since quarter-end: -39.9% from the close on the first trading day after the quarter ended (Jul 1, 2026) to the latest close (Nov 17, 2026). 13F does not report purchase prices — this is the price change since the quarter-end close, not a gain on any fund’s actual purchase.

Filing season: the Q3 2026 13F tracker follows every tracked fund’s filing for the quarter ended Sep 30, 2026, with its biggest buys and sells.

Charts

6.980.902024-11-192026-11-18

Closing prices (unadjusted for dividends), last 2 years — 501 trading days to Nov 18, 2026. Dashed lines mark 13F filing deadlines. Source: Yahoo Finance daily bars.

All institutions · Form 13F

Institutions holding209 of 8,857 filers
Long-only filers among them209
Change vs 2026 Q1+22 net · 205 entered · 183 exited
Shares reported, all filers299,577,796
Reported value, all filers$2.1B

Source: SEC Form 13F data sets — every filer's latest report for the quarter ended Jun 30, 2026, not just the tracked funds above; changes compare with the quarter ended Mar 31, 2026. Share counts and values are summed as reported in the filings (a small number of filers report values in thousands of dollars, so value totals are as-filed sums).

Company fundamentals

ExchangeNasdaq
IndustryBiological Products, (No Diagnostic Substances) (SIC 2836)
Revenue · FY2025$9.8M
Net income · FY2025$-109.0M
Total assets · FY2025$343.3M
Shares outstanding325,833,545
Market cap (at latest close)$1.3B

Source: SEC EDGAR company filings (submissions and company facts), collected Oct 30, 2026. Shares outstanding as reported Aug 11, 2026.

Short interest

Shares short · Oct 15, 202651,249,292
Share of shares outstanding15.73%
Days to cover11.56

Shares short at recent settlements — Jul 31, 2026: 46.7M · Aug 14, 2026: 46.7M · Aug 31, 2026: 46.8M · Sep 15, 2026: 51.4M · Sep 30, 2026: 55.0M · Oct 15, 2026: 51.2M.

Source: FINRA Equity Short Interest (biweekly settlement data). Shares outstanding from SEC filings as of Aug 11, 2026.

Fails to deliver

Shares failed to deliver · Oct 14, 20260
Share of shares outstanding0.00%
Fails as a share of short interest · Oct 15, 20260.0%

Fails to deliver at recent settlements — Jul 31, 2026: 0 · Aug 14, 2026: 0 · Aug 31, 2026: 0 · Sep 15, 2026: 0 · Sep 30, 2026: 0 · Oct 14, 2026: 0.

Source: SEC Fails-to-Deliver data (semi-monthly files, published about two weeks after each settlement date). Each figure is the balance of shares not yet delivered on that date; a stock absent from that date’s file counts as zero. See our research on whether fails to deliver predict returns. Shares outstanding from SEC filings as of Aug 11, 2026.

Insider trading · Form 4

Data unavailable — no Form 4 transactions for this ticker were parsed in the last 90 days.

Planned sales · Form 144

FiledSellerRoleShares to sellMarket valueApprox. sale dateSource
Jul 10, 2026Nagendran SukumarOfficer200,000$1.3MJul 10, 2026SEC filing
Apr 10, 2026Nagendran SukumarOfficer200,000$926.0KApr 10, 2026SEC filing
Feb 27, 2026Rumana Haque-AhmedOfficer2,405$11.0KFeb 27, 2026SEC filing
Feb 4, 2026Rumana Haque-AhmedOfficer697$3.3KFeb 4, 2026SEC filing
Feb 4, 2026Sean McAuliffeAffiliate - Chief Business Officer914$4.3KFeb 4, 2026SEC filing
Feb 4, 2026Fred PorterAffiliate-Chief of Staff & Tech.Op.Officer889$4.2KFeb 4, 2026SEC filing
Feb 4, 2026Emily McGinnisAffiliate-Chief Pat. Adv. & Ext. Aff. Off.901$4.3KFeb 4, 2026SEC filing
Feb 4, 2026Kamran AlamOfficer1,655$7.8KFeb 4, 2026SEC filing
Jan 23, 2026Rumana Haque-AhmedOfficer30,052$153.0KJan 23, 2026SEC filing
Jan 23, 2026Sean McAuliffeAffiliate - Chief Business Officer46,064$234.5KJan 23, 2026SEC filing

A Form 144 notice is a planned sale, not a completed sale. Most recent first. Source: SEC Form 144 filings, 63,013 notices from Apr 13, 2023 to Oct 9, 2026.

Activist disclosure · Schedule 13D

FiledFormPrice change since disclosure
Jun 3, 2025SCHEDULE 13D/A+43.4% (close Jun 4, 2025 → Nov 17, 2026)

Reference close is the first trading day after the filing (Jun 4, 2025). A Schedule 13D reports beneficial ownership, not a purchase — there is no transaction price to show. Source: SEC EDGAR Schedule 13D filings.

5% holders · Schedule 13D/G

FiledFilerFormShares% ownedEvent dateSource
Aug 14, 2026RA Capital Management, L.P.SC 13G/A32,886,2429.9%Jun 30, 2026SEC filing
Aug 13, 2026Morgan StanleySC 13G/A16,244,3395.1%Jun 30, 2026SEC filing
May 15, 2026RTW Investments, LPSC 13G/A20,689,0847.0%Mar 31, 2026SEC filing
May 15, 2026Vestal Point Capital, LPSC 13G/A18,000,0006.3%Mar 31, 2026SEC filing
Feb 17, 2026RTW Investments, LPSC 13G/A23,407,1338.3%Dec 31, 2025SEC filing
Feb 17, 2026Vestal Point Capital, LPSC 13G13,750,0005.0%Dec 31, 2025SEC filing
Feb 5, 2026FMR LLCSC 13G/A13,528,365.874.9%Dec 31, 2025SEC filing
Jan 21, 2026BlackRock, Inc.SC 13G/A17,852,2916.5%Dec 31, 2025SEC filing
Nov 14, 2025RA Capital Management, L.P.SC 13G/A27,662,4819.9%Sep 30, 2025SEC filing
Nov 14, 2025Octagon Capital Advisors LPSC 13G/A9,067,5003.3%Sep 30, 2025SEC filing

One filing is one row; a filing may list several reporters and the first is shown. Figures are as filed, including amendments that report zero shares after a transfer. Source: SEC Schedule 13D/G filings, 57,443 filings parsed to Oct 2, 2026.

Politician trading · U.S. Congress

Data unavailable — no congressional STOCK Act transactions for this ticker were parsed in the current window (as of Nov 16, 2026).

Committee jurisdiction

Industry: Biological Products, (No Diagnostic Substances) (SIC 2836). Standing committees with jurisdiction over this industry: Senate Committee on Health, Education, Labor, and Pensions, House Committee on Energy and Commerce.

None of the members who traded this stock in the current window sit on these committees.

Assignments are the current (119th Congress) rosters. A trade made in an earlier Congress may have been made under a different assignment. Jurisdiction is by industry (SEC SIC code), not by anything the company said or did. Same rule as our committee-jurisdiction study.

Government relations

Lobbying: 17 Lobbying Disclosure Act filings named this company as client, 2020–2026; most common issues: Health Issues (13), Medicare/Medicaid (12).

Federal contracts: no obligated amounts found for this ticker (USASpending, fiscal years 2021–2026).

Lobbying filings are matched by company core name; a filing can match more than one ticker. Contract amounts are obligated amounts (money committed, not money spent), matched by recipient name — contracts under a subsidiary’s name can be missed. Sources: Senate Lobbying Disclosure Act filings; USAspending.gov. See Methodology.

Screens & lenses

Red Flags

· Distress Risk (Altman Z″) — Altman Z″-Score below 1.10

Key figures

· Distress Risk (Altman Z″) — Z″-Score: -0.53 · Working capital / assets: 0.87 · Retained earnings / assets: -2.07 · EBIT / assets: -0.32 · Equity / liabilities: 2.56

Financial screens are computed from SEC company financial statements; red-flag models are screens, not verdicts — see Methodology.

Signal record

· Insider BEST — appeared in 2 of the last 20 quarterly lists; latest 2023 Q3, ranked #9 of 50.

Also held by the tracked funds that hold TSHA — ranked by lift, the co-holding pattern described in Methodology: ACADIA PHARMACEUTICALS INC (ACAD) · FAETH THERAPEUTICS INC (FTH) · Kodiak Sciences Inc. (KOD) · KYMERA THERAPEUTICS INC (KYMR) · MADRIGAL PHARMACEUTICALS INC (MDGL) · PTC THERAPEUTICS, INC. (PTCT) · UroGen Pharma Ltd. (URGN) · Aktis Oncology, Inc. (AKTS).

Recent 8-K filings

FiledItemsSource
Nov 12, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Aug 11, 20262.02 Results of Operations and Financial Condition · 9.01 Financial Statements and ExhibitsSEC filing
Jun 25, 20261.01 Entry into a Material Definitive Agreement · 8.01 Other Events · 9.01 Financial Statements and ExhibitsSEC filing

Source: SEC EDGAR Form 8-K filings, latest first. Amendments (Form 8-K/A) are labeled as such. Item labels are the SEC's item titles; a filing can carry several items. Item 5.02 covers both departures and appointments, which this index does not distinguish.

Related

ACADIA PHARMACEUTICALS INC (ACAD) · Track Record: how the signals scored · Practice timing on TSHA

One email a week: the week’s new filings and research. Subscribe free

← TSEM  ·  TSLA →

Open the interactive tool →Live screens, charts and backtests for every tracked stock, fund and signal — free, no sign-up.